TW202122410A - 鈣敏感受體激動劑化合物及其應用 - Google Patents

鈣敏感受體激動劑化合物及其應用 Download PDF

Info

Publication number
TW202122410A
TW202122410A TW109143251A TW109143251A TW202122410A TW 202122410 A TW202122410 A TW 202122410A TW 109143251 A TW109143251 A TW 109143251A TW 109143251 A TW109143251 A TW 109143251A TW 202122410 A TW202122410 A TW 202122410A
Authority
TW
Taiwan
Prior art keywords
arg
cys
peptide
variations
xaa
Prior art date
Application number
TW109143251A
Other languages
English (en)
Chinese (zh)
Inventor
吳方舟
張瑾
高菲
吳然
廖成
王雷
Original Assignee
大陸商北京拓界生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京拓界生物醫藥科技有限公司 filed Critical 大陸商北京拓界生物醫藥科技有限公司
Publication of TW202122410A publication Critical patent/TW202122410A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW109143251A 2019-12-09 2020-12-08 鈣敏感受體激動劑化合物及其應用 TW202122410A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911250088.1 2019-12-09
CN201911250088 2019-12-09

Publications (1)

Publication Number Publication Date
TW202122410A true TW202122410A (zh) 2021-06-16

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109143251A TW202122410A (zh) 2019-12-09 2020-12-08 鈣敏感受體激動劑化合物及其應用

Country Status (11)

Country Link
US (1) US20230041996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4091623A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796013B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110789A (cg-RX-API-DMAC7.html)
CN (2) CN118496313A (cg-RX-API-DMAC7.html)
AU (1) AU2020399030B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159744A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006892A (cg-RX-API-DMAC7.html)
TW (1) TW202122410A (cg-RX-API-DMAC7.html)
WO (1) WO2021115272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
CN121378400A (zh) * 2024-10-24 2026-01-23 成都诺和晟泰生物科技有限公司 一种多肽化合物、包含其的组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN103270018A (zh) * 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
WO2012069421A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
PT2717896T (pt) * 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Also Published As

Publication number Publication date
US20230041996A1 (en) 2023-02-09
AU2020399030A1 (en) 2022-06-23
KR20220110789A (ko) 2022-08-09
EP4091623A1 (en) 2022-11-23
CN114222578B (zh) 2024-06-25
CN118496313A (zh) 2024-08-16
EP4091623A4 (en) 2024-01-03
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
WO2021115272A1 (zh) 2021-06-17
BR112022011127A2 (pt) 2022-08-23
CN114222578A (zh) 2022-03-22
JP7796013B2 (ja) 2026-01-08
AU2020399030B2 (en) 2026-04-09
JP2023504904A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
AU2021204313B2 (en) Modulation of complement activity
TWI689515B (zh) Gip-glp-1雙重促效劑化合物及方法
AU2002336783B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
US20250186557A1 (en) Manufacture, formulation and dosing of apraglutide
JP7796013B2 (ja) カルシウム感知受容体アゴニスト化合物及びその使用
RS62630B9 (sr) Modulatori aktivnosti komplementa
EP4021921A1 (en) Compstatin analogues and their medical uses
CN120981479A (zh) Gip/glp1/gcg三受体激动剂及其用途
EP1422240A2 (en) Analogs of nociceptin
AU2021222972A1 (en) Molecules targeting RAS protein
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
CA3193223A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
WO2022052471A1 (zh) 双特异性融合多肽化合物
HK40069562B (en) Calcium-sensing receptor agonist compound and application thereof
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
WO2022257958A1 (zh) 一种钙敏感受体激动剂的组合物及其应用
CN117136192A (zh) 缀合的铁调素模拟物
JPS6168499A (ja) 新規ペプチド